Role of Nucleocapsid Protein Antigen Detection for Safe End of Isolation of SARS-CoV-2 Infected Patients with Long Persistence of Viral RNA in Respiratory Samples.
RT-PCR
SARS-CoV-2
antigen test
isolation and discharge recommendations
virus culture
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Sep 2021
07 Sep 2021
Historique:
received:
17
08
2021
revised:
31
08
2021
accepted:
03
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
In SARS-CoV-2 infection, viral RNA may persist in respiratory samples for several weeks after the resolution of symptoms. Criteria to assess the end of infectivity are not unequivocally defined. In some countries, time from diagnosis is the unique criterion used, in addition to symptom cessation. This study evaluates the role of the Lumipulse A total of 671 nasopharyngeal swabs from patients diagnosed with infection at least 21 days before were assessed by RT-PCR and LAA, and the role of LAA in predicting the absence of infectivity was evaluated by virus cell culture. Viable virus was present in 10/138 cultured samples. Eight out of ten infective patients suffered from a concomitant disease, predisposing them to long-term shedding of infective virus. In particular, infectious virus was isolated from 10/20 RT-PCR+/LAA+ cultured samples, whereas no viable virus was found in all 118 RT-PCR+/LAA- cultured swabs. LLA and RT-PCR agreed in 484/671 (72.1%) samples, with 100% and 26.7% concordance in RT-PCR negative and positive samples, respectively. Viable virus can be found ≥21 days after diagnosis in immunocompromised or severely ill patients. LAA better than RT-PCR predicts non-infectivity of patients and can be safely used to end isolation in cases with long persistence of viral RNA in the respiratory tract.
Sections du résumé
BACKGROUND
BACKGROUND
In SARS-CoV-2 infection, viral RNA may persist in respiratory samples for several weeks after the resolution of symptoms. Criteria to assess the end of infectivity are not unequivocally defined. In some countries, time from diagnosis is the unique criterion used, in addition to symptom cessation. This study evaluates the role of the Lumipulse
METHODS
METHODS
A total of 671 nasopharyngeal swabs from patients diagnosed with infection at least 21 days before were assessed by RT-PCR and LAA, and the role of LAA in predicting the absence of infectivity was evaluated by virus cell culture.
RESULTS
RESULTS
Viable virus was present in 10/138 cultured samples. Eight out of ten infective patients suffered from a concomitant disease, predisposing them to long-term shedding of infective virus. In particular, infectious virus was isolated from 10/20 RT-PCR+/LAA+ cultured samples, whereas no viable virus was found in all 118 RT-PCR+/LAA- cultured swabs. LLA and RT-PCR agreed in 484/671 (72.1%) samples, with 100% and 26.7% concordance in RT-PCR negative and positive samples, respectively.
CONCLUSIONS
CONCLUSIONS
Viable virus can be found ≥21 days after diagnosis in immunocompromised or severely ill patients. LAA better than RT-PCR predicts non-infectivity of patients and can be safely used to end isolation in cases with long persistence of viral RNA in the respiratory tract.
Identifiants
pubmed: 34575147
pii: jcm10184037
doi: 10.3390/jcm10184037
pmc: PMC8469917
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Cassa di Risparmio di Perugia
ID : 19663
Références
J Infect. 2020 Oct;81(4):647-679
pubmed: 32407758
J Med Virol. 2020 Nov;92(11):2298-2301
pubmed: 32369214
J Infect Chemother. 2021 Feb;27(2):406-409
pubmed: 33183963
J Infect. 2020 Sep;81(3):e90-e92
pubmed: 32574567
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Osong Public Health Res Perspect. 2020 Jun;11(3):112-117
pubmed: 32528816
J Virol Methods. 2021 May;291:114102
pubmed: 33607117
Front Med (Lausanne). 2021 Jun 17;8:648660
pubmed: 34239886
J Infect Dis. 2021 Jan 4;223(1):23-27
pubmed: 33089317
Int J Infect Dis. 2021 Apr;105:7-14
pubmed: 33556612
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):1-12
pubmed: 33037944
Int J Infect Dis. 2021 Apr;105:391-396
pubmed: 33647511
Ann Transl Med. 2021 Apr;9(8):665
pubmed: 33987363
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
J Infect Dis. 2020 Sep 1;222(7):1103-1107
pubmed: 32702095
J Infect Dis. 2021 May 20;223(9):1522-1527
pubmed: 33556961
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
Air Qual Atmos Health. 2020 Aug 1;:1-7
pubmed: 32837620
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
J Econ Surv. 2021 Apr 18;:
pubmed: 34230772
Int J Environ Res Public Health. 2021 Jun 17;18(12):
pubmed: 34204403
N Engl J Med. 2021 Feb 18;384(7):671-673
pubmed: 33503337
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Int J Infect Dis. 2020 Oct;99:397-402
pubmed: 32800855
Biochem Biophys Res Commun. 2005 Apr 15;329(3):1147-51
pubmed: 15752773
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Emerg Infect Dis. 2020 Nov;26(11):2701-2704
pubmed: 32749957
J Clin Med. 2021 Jan 15;10(2):
pubmed: 33467628
JAMA. 2020 Dec 1;324(21):2153-2154
pubmed: 33185688
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283147
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Am J Infect Control. 2020 Jun;48(6):725-726
pubmed: 32317126